Compare Merck & Co., Inc. (MRK) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs United Parcel Service Inc — how do they compare? Merck & Co., Inc. trades at $148.23 (market cap $366.28B), while United Parcel Service Inc trades at $99.5 (market cap $85.49B). The key difference: Merck & Co., Inc. is far larger — about 4.3× United Parcel Service Inc's market cap, and United Parcel Service Inc pays the higher dividend (6.53%). Which is the better fit depends on your goals.
| MRK | UPS | |
|---|---|---|
Market Cap | $366.28B | $85.49B |
Sector | Health | Industrials |
52-Week High | $156.43 | $120.00 |
52-Week Low | $77.60 | $82.58 |
Enterprise Value | $413.04B | $109.51B |
Dividend Yield | 2.29% | 6.53% |
Volume | — | 2,288,643 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
UPS stock trades at $100.48, down 1.78% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. The company announced a $2B+ global investment to enhance logistics and appointed a new Chief Global Operations Officer, signaling strategic shifts. Valuation metrics include a P/E of 18.68 and P/S of 0.95, with a dividend yield of 6.2% based on the $1.64 per share payout.
The outlook is mixed: analyst consensus leans neutral with a $117.90 price target, but risks include declining net income margins and high dividend payout ratios limiting investment flexibility. Upside potential exists from efficiency gains and global expansion, while macroeconomic pressures and competitive threats pose challenges for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
